Jefferies Group Analysts Begin Coverage on Ironwood Pharmaceuti (IRWD)

By admin | 6 years ago

Analysts at Jefferies Group (NYSE: JEF) started coverage on shares of Ironwood Pharmaceuti (NASDAQ: IRWD) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.

Several other analysts have also recently commented on the stock. Analysts at UBS AG (NYSE: UBS) initiated coverage on shares of Ironwood Pharmaceuti in a research note to investors on Thursday, April 12nd. They set a “neutral” rating and a $14.00 price target on the stock. Separately, analysts at Wedbush downgraded shares of Ironwood Pharmaceuti from an “outperform” rating to an “underperform” rating in a research note to investors on Monday, March 5th. Finally, analysts at Cantor Fitzgerald downgraded shares of Ironwood Pharmaceuti from a “hold” rating to a “sell” rating in a research note to investors on Wednesday, February 29th. They now have a $10.00 price target on the stock.

Ironwood Pharmaceuti traded down 3.71% on Monday, hitting $12.71. Ironwood Pharmaceuti has a 1-year low of $9.97 and a 1-year high of $16.50. The company’s market cap is $1.319 billion.

Ironwood Pharmaceuti last issued its quarterly earnings data on Tuesday, May 1st. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.23) by $0.11. The company’s quarterly revenue was up 19.6% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuti will post $0.10 earnings per share next quarter.

Ironwood Pharmaceuticals, Inc., formerly Microbia, Inc. is an entrepreneurial pharmaceutical company that discovers, develops and focuses to commercialize medicines targeting important therapeutic needs.

About the author